A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion

NCT02153476 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Symptomatic Focal Vitreomacular Adhesion

Interventions

DRUG: 2.0mg of ALG-1001
DRUG: Balanced Salt Solution

Sponsor

Allegro Ophthalmics, LLC